CG
AMLX icon

Cutler Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cutler Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$1K – 3740
2023
Q2 		$1K Buy
+500
New +$13.5K ﹤0.01% 3179
2022
Q4 		– Sell
-35,500
Closed -$56K – 4321
2022
Q3 		$56K Buy
+35,500
New +$886K ﹤0.01% 1802

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's AMLX Position: Q1 2024 in Review

Cutler Group increased its Amylyx Pharmaceuticals (AMLX) stake by 11% in Q1 2024, buying an estimated $1.31K and bringing the position to 1,000 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1791.

Cutler Group first reported a position in AMLX in Q2 2022 and has held it in 6 quarters since. The position peaked at $324K in Q3 2022. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Cutler Group held 1,000 shares of Amylyx Pharmaceuticals worth $2K as of Q1 2024.
  • Cutler Group bought 100 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $1.31K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1791 holding.
  • Cutler Group first reported a position in Amylyx Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
  • Cutler Group's Amylyx Pharmaceuticals position peaked at $324K in Q3 2022.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.